Analysts’ Viewpoint
Rise in R&D spending by pharmaceutical companies and increase in focus on development of personalized medicines and orphan drugs are driving the global market. Pharmaceutical and biotech companies require a range of services to support their drug development efforts. This is fueling the drug discovery outsourcing market demand. Increase in complexity of drug development and advancements in technology & automation offer lucrative market opportunities for market players.
The market includes a diverse range of service providers, including contract research organizations (CROs) and academic research organizations (AROs). Outsourcing can also help reduce drug development costs. New technologies such as AI, ML, and robotics are being used to improve the efficiency and accuracy of drug discovery activities, which is augmenting growth of the drug discovery outsourcing industry.
Drug discovery is a complex and time-consuming process that involves identification, development, and testing of new medications to treat various diseases. The process typically involves several stages, including target identification, lead discovery, lead optimization, preclinical testing, clinical trials, and regulatory approval.
Outsourcing involves hiring a third-party organization to perform some or all of the drug discovery process. It can also be used for clinical trials and regulatory approval, although these are typically more complex and may require more specialized expertise. Chemical and biology services are the primary types of drug discovery outsourcing.
Outsourcing allows pharmaceutical companies to eliminate the need to invest in expensive laboratory equipment and specialized personnel, thus reducing overhead costs. Outsourcing firms have a team of highly skilled scientists and researchers with expertise in different areas of drug discovery. Outsourcing can also help companies access new technologies and techniques that they may not have otherwise been able to afford or implement on their own. These advantages of drug discovery outsourcing fuel market development.
The global pharmaceutical industry has experienced a significant rise in research and development (R&D) spending in the past few years, driven by surge in demand for innovative drugs to treat a range of diseases, increase in prevalence of chronic diseases such as cancer and diabetes, and emergence of new technologies such as gene therapy and immunotherapy. However, drug discovery is a complex and time-consuming process that requires significant investment in terms of time, money, and expertise.
Outsourcing enables pharmaceutical companies to focus on the commercialization of products, while outsourcing companies take care of the research and development process. These companies have a team of experts with knowledge of various therapeutic areas, which helps in accelerating the drug discovery process. Hence, pharmaceutical companies are investing significantly on R&D.
The drug discovery process is complex, and any errors or delays could result in significant costs and delays in bringing a drug to market. Outsourcing firms have the expertise and experience to manage the risks involved and help pharmaceutical companies mitigate potential losses. Outsourcing can help pharmaceutical companies reduce costs and accelerate the drug discovery process, allowing them to bring innovative drugs to market faster and more efficiently.
Pharmaceutical companies are focused on streamlining internal R&D systems, and hence are employing external resources for the development of newer drugs with higher success rates. These companies are focused on outsourcing both the discovery of new therapeutic agents and their thorough validation to drug discovery service providers, as these have become the key priorities of drug discovery research.
Companies have entered into collaborations with academia and drug discovery service providers for the integration of human genetics research in drug discovery & development programs. Moreover, genomics and proteomics find a range of applications in drug discovery, such as for safety biomarker development & application, target identification & validation, and novel antibody drug development.
Personalized medicine involves usage of patient-specific data to develop tailored therapies that are more effective and have fewer side effects. This requires deep understanding of the biology of disease and mechanisms underlying drug efficacy, which can be achieved through outsourcing drug discovery activities.
Adoption of orphan drugs has been increasing owing to rise in awareness about treatment options available for orphan diseases. Moreover, prevalence of orphan diseases has been increasing, creating a need to expand the production of orphan drugs. Drug manufacturers are focused on the development of therapies for orphan diseases. Eighteen orphan drugs were approved by the FDA in 2022.
Production of orphan drugs provides higher return on investment to manufacturers. Hence, pharmaceutical companies are focusing on the manufacturing of orphan drugs for rare diseases. Companies engaged in the marketing of orphan drugs generate high revenue, owing to high cost of orphan drugs. Development of phase-III orphan drugs costs over 50% of that of non-orphan drugs owing to various benefits offered such as fee waivers and tax credits.
In terms of services, the chemical services segment accounted for the largest global drug discovery outsourcing market share in 2022. The segment is likely to lead the global market in the next few years.
Chemical services in drug discovery outsourcing refer to the synthesis of small molecules. This involves the design and synthesis of new compounds that can potentially be used as drugs and optimization of existing molecules to improve their efficacy and safety. Chemical services also include production of libraries of small molecules for high-throughput screening.
Small molecules are preferred over other types of drugs because they can be easily synthesized, are more stable, and have better pharmacokinetic properties. This has led to a growing need for chemical services in drug discovery outsourcing to support the development of small molecule drugs.
Increase in complexity of drug discovery is fueling demand for chemical services. Pharmaceutical and biotech companies are turning to outsourcing to access the expertise and resources they need as drug targets become more challenging and the drug development process becomes more intricate.
Chemical service providers are able to offer specialized knowledge and experience in the design and synthesis of small molecules, which can help accelerate the drug discovery process. Furthermore, the chemical services segment is benefiting from advancements in technology and automation.
Based on therapeutic area, the oncology segment is likely to lead the global market during the forecast period. Increase in incidence of cancer across the globe is fueling demand for more effective treatments. Cancer is one of the leading causes of death globally, and the need for new and innovative therapies is critical.
Outsourcing drug discovery activities in oncology could provide several advantages to pharmaceutical and biotech companies. One of the primary benefits is access to a broader range of expertise and resources, which can help accelerate the drug discovery process and improve the likelihood of success. Outsourcing could also help reduce development costs and speed up time to market, which is essential in the highly competitive oncology market.
Drug discovery outsourcing providers specializing in oncology have a deep understanding of the complex biology of cancer and the mechanisms underlying tumor growth and progression. This expertise can be leveraged to develop more targeted and personalized therapies that are tailored to the unique needs of individual patients.
The oncology segment is benefiting from increasing availability of advanced technologies and platforms that can support drug discovery efforts.
In terms of drug type, the small molecules segment is projected to account for major share of the global drug discovery outsourcing market during the forecast period.
Small molecules are organic compounds with a low molecular weight that are the basis of most drugs. The primary advantage of small molecules is the ability to easily penetrate cell membranes, making them effective at targeting intracellular proteins and enzymes. This makes them a preferred option for many therapeutic areas, including oncology, infectious diseases, and neurological disorders.
Small molecules also have a long history of usage in drug development, with several approved drugs on the market being small molecules. Thus, knowledge and experience in the design and synthesis of small molecules could help accelerate the drug discovery process.
Small molecules are generally more stable than other types of drugs, such as biologics, making them easier to manufacture and store. This can help reduce development costs and improve the scalability of drug production.
Small molecules are amenable to high-throughput screening, which is a key step in the drug discovery process. Large libraries of small molecules can be rapidly screened for their potential to interact with specific targets, allowing researchers to identify promising leads for further optimization.
As per drug discovery outsourcing trends, North America accounted for major share of the global drug discovery outsourcing market in 2022. The region is anticipated to dominate the global industry during the forecast period, with the U.S. being the largest contributor to revenue growth.
Increase in incidence of cardiovascular and neurovascular diseases across is a key factor fueling the market in the region. Furthermore, strong presence of prominent players and their effective strategies are expected to drive market progress in the region.
Availability of advanced technologies and platforms also contributed to market growth in North America. The region is a hub for innovation in areas such as artificial intelligence, high-throughput screening, and genomics, which are critical to the drug discovery process.
The drug discovery outsourcing market size in Asia Pacific is projected to increase in the near future, owing to high disease prevalence, emergence of local companies, and presence of a large patient pool. Multiple strategic initiatives implemented by innovative companies are expected to bolster market expansion in the region.
Leading players operating in the global market are Charles River Laboratories International, Inc., WuXi AppTec Co., Ltd., Albany Molecular Research, Inc., GVK Biosciences Private Limited, Sygnature Discovery, Pharmaron Beijing Co., Ltd., Domainex Ltd., Thermo Fisher Scientific, Inc., Jubilant Biosys Ltd., Evotec SE, Eurofins Discovery, and GenScript Biotech Corporation.
As per the drug discovery outsourcing market forecast, companies are engaged in merger & acquisition, strategic partnerships, and new product launches to expand industry presence. Key players are focusing on following the market trends to avail lucrative revenue opportunities.
The drug discovery outsourcing market report profiles the top players based on various parameters including company overview, financial summary, strategies, product portfolio, segments, and recent advancements.
| Attribute | Detail |
|---|---|
|
Size in 2022 |
US$ 3.6 Bn |
|
Forecast (Value) in 2031 |
More than US$ 7.5 Bn |
|
Growth Rate (CAGR) |
7.8% |
|
Forecast Period |
2023-2031 |
|
Historical Data Available for |
2017-2021 |
|
Quantitative Units |
US$ Bn for Value |
|
Market Analysis |
It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
It was valued at US$ 3.6 Bn in 2022
It is projected to reach more than US$ 7.5 Bn in 2031
It is likely to expand at a CAGR of 7.8% from 2023 to 2031
The small molecules segment accounted for leading share in 2022
North America is expected to be a more lucrative region during the forecast period
Charles River Laboratories International, Inc., WuXi AppTec Co., Ltd., Albany Molecular Research Inc., GVK Biosciences Private Limited, Sygnature Discovery, Pharmaron Beijing Co., Ltd., Domainex Ltd., Thermo Fisher Scientific, Inc., Jubilant Biosys Ltd., Evotec SE, Eurofins Discovery, and GenScript Biotech Corporation
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Drug Discovery Outsourcing Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Drug Discovery Outsourcing Market Analysis and Forecast, 2017-2031
5. Key Insights
5.1. Technological Advancements
5.2. Overview: Integrated Drug Discovery (IDD) outsourcing
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Drug Discovery Outsourcing Market Analysis and Forecast, by Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Type, 2017-2031
6.3.1. Chemistry Services
6.3.2. Biology Services
6.4. Market Attractiveness Analysis, by Type
7. Global Drug Discovery Outsourcing Market Analysis and Forecast, by Drug Molecule
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Drug Molecule, 2017-2031
7.3.1. Small Molecules
7.3.2. Large Molecules
7.4. Market Attractiveness Analysis, by Drug Molecule
8. Global Drug Discovery Outsourcing Market Analysis and Forecast, by Discovery Approach
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Discovery Approach, 2017-2031
8.3.1. Empirical Drug Discovery
8.3.2. Rational Drug Discovery
8.4. Market Attractiveness Analysis, by Discovery Approach
9. Global Drug Discovery Outsourcing Market Analysis and Forecast, by Therapeutic Area
9.1. Introduction & Definition
9.2. Key Findings/Developments
9.3. Market Value Forecast, by Therapeutic Area, 2017-2031
9.3.1. Anti-infective
9.3.2. Cardiovascular
9.3.3. Central Nervous System
9.3.4. Dermatology
9.3.5. Endocrine
9.3.6. Gastrointestinal
9.3.7. Genitourinary System
9.3.8. Immunomodulation
9.3.9. Oncology
9.3.10. Ophthalmology
9.3.11. Respiratory System
9.3.12. Others
9.4. Market Attractiveness Analysis, by Therapeutic Area
10. Global Drug Discovery Outsourcing Market Analysis and Forecast, by Workflow
10.1. Introduction & Definition
10.2. Key Findings/Developments
10.3. Market Value Forecast, by Workflow, 2017-2031
10.3.1. Target Identification and Screening
10.3.2. Lead Identification and Candidate Optimization
10.3.3. Development of Disease Models
10.3.4. Pre-formulation Studies
10.3.5. Entire Clinical Trials
10.3.6. Others
10.4. Market Attractiveness Analysis, by Workflow
11. Global Drug Discovery Outsourcing Market Analysis and Forecast, by End-user
11.1. Introduction & Definition
11.2. Key Findings/Developments
11.3. Market Value Forecast, by Discovery Approach, 2017-2031
11.3.1. Pharmaceutical Companies
11.3.2. Biotechnology Companies
11.3.3. Academic Institutes
11.4. Market Attractiveness Analysis, by End-user
12. Global Drug Discovery Outsourcing Market Analysis and Forecast, by Region
12.1. Key Findings
12.2. Market Value Forecast, by Region, 2017-2031
12.2.1. North America
12.2.2. Europe
12.2.3. Asia Pacific
12.2.4. Latin America
12.2.5. Middle East & Africa
12.3. Market Attractiveness Analysis, by Region
13. North America Drug Discovery Outsourcing Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Type, 2017-2031
13.2.1. Chemistry Services
13.2.2. Biology Services
13.3. Market Value Forecast, by Drug Molecule, 2017-2031
13.3.1. Small Molecules
13.3.2. Large Molecules
13.4. Market Value Forecast, by Discovery Approach, 2017-2031
13.4.1. Empirical Drug Discovery
13.4.2. Rational Drug Discovery
13.5. Market Value Forecast, by Therapeutic Area, 2017-2031
13.5.1. Anti-infective
13.5.2. Cardiovascular
13.5.3. Central Nervous System
13.5.4. Dermatology
13.5.5. Endocrine
13.5.6. Gastrointestinal
13.5.7. Genitourinary System
13.5.8. Immunomodulation
13.5.9. Oncology
13.5.10. Ophthalmology
13.5.11. Respiratory System
13.5.12. Others
13.6. Market Value Forecast, by Workflow, 2017-2031
13.6.1. Target Identification and Screening
13.6.2. Lead Identification and Candidate Optimization
13.6.3. Development of Disease Models
13.6.4. Pre-formulation Studies
13.6.5. Entire Clinical Trials
13.6.6. Others
13.7. Market Value Forecast, by End-user, 2017-2031
13.7.1. Pharmaceutical Companies
13.7.2. Biotechnology Companies
13.7.3. Academic Institutes
13.8. Market Value Forecast, by Country, 2017-2031
13.8.1. U.S.
13.8.2. Canada
13.9. Market Attractiveness Analysis
13.9.1. By Type
13.9.2. By Drug Molecule
13.9.3. By Discovery Approach
13.9.4. By Therapeutic Area
13.9.5. By Workflow
13.9.6. By End-user
13.9.7. By Country
14. Europe Drug Discovery Outsourcing Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Type, 2017-2031
14.2.1. Chemistry Services
14.2.2. Biology Services
14.3. Market Value Forecast, by Drug Molecule, 2017-2031
14.3.1. Small Molecules
14.3.2. Large Molecules
14.4. Market Value Forecast, by Discovery Approach, 2017-2031
14.4.1. Empirical Drug Discovery
14.4.2. Rational Drug Discovery
14.5. Market Value Forecast, by Therapeutic Area, 2017-2031
14.5.1. Anti-infective
14.5.2. Cardiovascular
14.5.3. Central Nervous System
14.5.4. Dermatology
14.5.5. Endocrine
14.5.6. Gastrointestinal
14.5.7. Genitourinary System
14.5.8. Immunomodulation
14.5.9. Oncology
14.5.10. Ophthalmology
14.5.11. Respiratory System
14.5.12. Others
14.6. Market Value Forecast, by Workflow, 2017-2031
14.6.1. Target Identification and Screening
14.6.2. Lead Identification and Candidate Optimization
14.6.3. Development of Disease Models
14.6.4. Pre-formulation Studies
14.6.5. Entire Clinical Trials
14.6.6. Others
14.7. Market Value Forecast, by End-user, 2017-2031
14.7.1. Pharmaceutical Companies
14.7.2. Biotechnology Companies
14.7.3. Academic Institutes
14.8. Market Value Forecast, by Country/Sub-region, 2017-2031
14.8.1. Germany
14.8.2. U.K.
14.8.3. France
14.8.4. Italy
14.8.5. Spain
14.8.6. Rest of Europe
14.9. Market Attractiveness Analysis
14.9.1. By Type
14.9.2. By Drug Molecule
14.9.3. By Discovery Approach
14.9.4. By Therapeutic Area
14.9.5. By Workflow
14.9.6. By End-user
14.9.7. By Country/Sub-region
15. Asia Pacific Drug Discovery Outsourcing Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Type, 2017-2031
15.2.1. Chemistry Services
15.2.2. Biology Services
15.3. Market Value Forecast, by Drug Molecule, 2017-2031
15.3.1. Small Molecules
15.3.2. Large Molecules
15.4. Market Value Forecast, by Discovery Approach, 2017-2031
15.4.1. Empirical Drug Discovery
15.4.2. Rational Drug Discovery
15.5. Market Value Forecast, by Therapeutic Area, 2017-2031
15.5.1. Anti-infective
15.5.2. Cardiovascular
15.5.3. Central Nervous System
15.5.4. Dermatology
15.5.5. Endocrine
15.5.6. Gastrointestinal
15.5.7. Genitourinary System
15.5.8. Immunomodulation
15.5.9. Oncology
15.5.10. Ophthalmology
15.5.11. Respiratory System
15.5.12. Others
15.6. Market Value Forecast, by Workflow, 2017-2031
15.6.1. Target Identification and Screening
15.6.2. Lead Identification and Candidate Optimization
15.6.3. Development of Disease Models
15.6.4. Pre-formulation Studies
15.6.5. Entire Clinical Trials
15.6.6. Others
15.7. Market Value Forecast, by End-user, 2017-2031
15.7.1. Pharmaceutical Companies
15.7.2. Biotechnology Companies
15.7.3. Academic Institutes
15.8. Market Value Forecast, by Country/Sub-region, 2017-2031
15.8.1. China
15.8.2. Japan
15.8.3. India
15.8.4. Australia & New Zealand
15.8.5. Rest of Asia Pacific
15.9. Market Attractiveness Analysis
15.9.1. By Type
15.9.2. By Drug Molecule
15.9.3. By Discovery Approach
15.9.4. By Therapeutic Area
15.9.5. By Workflow
15.9.6. By End-user
15.9.7. By Country/Sub-region
16. Latin America Drug Discovery Outsourcing Market Analysis and Forecast
16.1. Introduction
16.1.1. Key Findings
16.2. Market Value Forecast, by Type, 2017-2031
16.2.1. Chemistry Services
16.2.2. Biology Services
16.3. Market Value Forecast, by Drug Molecule, 2017-2031
16.3.1. Small Molecules
16.3.2. Large Molecules
16.4. Market Value Forecast, by Discovery Approach, 2017-2031
16.4.1. Empirical Drug Discovery
16.4.2. Rational Drug Discovery
16.5. Market Value Forecast, by Therapeutic Area, 2017-2031
16.5.1. Anti-infective
16.5.2. Cardiovascular
16.5.3. Central Nervous System
16.5.4. Dermatology
16.5.5. Endocrine
16.5.6. Gastrointestinal
16.5.7. Genitourinary System
16.5.8. Immunomodulation
16.5.9. Oncology
16.5.10. Ophthalmology
16.5.11. Respiratory System
16.5.12. Others
16.6. Market Value Forecast, by Workflow, 2017-2031
16.6.1. Target Identification and Screening
16.6.2. Lead Identification and Candidate Optimization
16.6.3. Development of Disease Models
16.6.4. Pre-formulation Studies
16.6.5. Entire Clinical Trials
16.6.6. Others
16.7. Market Value Forecast, by End-user, 2017-2031
16.7.1. Pharmaceutical Companies
16.7.2. Biotechnology Companies
16.7.3. Academic Institutes
16.8. Market Value Forecast, by Country/Sub-region, 2017-2031
16.8.1. Brazil
16.8.2. Mexico
16.8.3. Rest of Latin America
16.9. Market Attractiveness Analysis
16.9.1. By Type
16.9.2. By Drug Molecule
16.9.3. By Discovery Approach
16.9.4. By Therapeutic Area
16.9.5. By Workflow
16.9.6. By End-user
16.9.7. By Country/Sub-region
17. Middle East & Africa Drug Discovery Outsourcing Market Analysis and Forecast
17.1. Introduction
17.1.1. Key Findings
17.2. Market Value Forecast, by Type, 2017-2031
17.2.1. Chemistry Services
17.2.2. Biology Services
17.3. Market Value Forecast, by Drug Molecule, 2017-2031
17.3.1. Small Molecules
17.3.2. Large Molecules
17.4. Market Value Forecast, by Discovery Approach, 2017-2031
17.4.1. Empirical Drug Discovery
17.4.2. Rational Drug Discovery
17.5. Market Value Forecast, by Therapeutic Area, 2017-2031
17.5.1. Anti-infective
17.5.2. Cardiovascular
17.5.3. Central Nervous System
17.5.4. Dermatology
17.5.5. Endocrine
17.5.6. Gastrointestinal
17.5.7. Genitourinary System
17.5.8. Immunomodulation
17.5.9. Oncology
17.5.10. Ophthalmology
17.5.11. Respiratory System
17.5.12. Others
17.6. Market Value Forecast, by Workflow, 2017-2031
17.6.1. Target Identification and Screening
17.6.2. Lead Identification and Candidate Optimization
17.6.3. Development of Disease Models
17.6.4. Pre-formulation Studies
17.6.5. Entire Clinical Trials
17.6.6. Others
17.7. Market Value Forecast, by End-user, 2017-2031
17.7.1. Pharmaceutical Companies
17.7.2. Biotechnology Companies
17.7.3. Academic Institutes
17.8. Market Value Forecast, by Country/Sub-region, 2017-2031
17.8.1. GCC Countries
17.8.2. South Africa
17.8.3. Rest of MEA
17.9. Market Attractiveness Analysis
17.9.1. By Type
17.9.2. By Drug Molecule
17.9.3. By Discovery Approach
17.9.4. By Therapeutic Area
17.9.5. By Workflow
17.9.6. By End-user
17.9.7. By Country/Sub-region
18. Competition Landscape
18.1. Market Player - Competitive Matrix (by tier and size of companies)
18.2. Market Share Analysis, by Company (2022)
18.3. Company Profiles
18.3.1. Charles River Laboratories International, Inc.
18.3.1.1. Company Overview
18.3.1.2. Product Portfolio
18.3.1.3. SWOT Analysis
18.3.1.4. Financial Overview
18.3.1.5. Strategic Overview
18.3.2. WuXi AppTec Co., Ltd.
18.3.2.1. Company Overview
18.3.2.2. Product Portfolio
18.3.2.3. SWOT Analysis
18.3.2.4. Financial Overview
18.3.2.5. Strategic Overview
18.3.3. Albany Molecular Research Inc.
18.3.3.1. Company Overview
18.3.3.2. Product Portfolio
18.3.3.3. SWOT Analysis
18.3.3.4. Financial Overview
18.3.3.5. Strategic Overview
18.3.4. GVK Biosciences Private Limited
18.3.4.1. Company Overview
18.3.4.2. Product Portfolio
18.3.4.3. SWOT Analysis
18.3.4.4. Financial Overview
18.3.4.5. Strategic Overview
18.3.5. Sygnature Discovery
18.3.5.1. Company Overview
18.3.5.2. Product Portfolio
18.3.5.3. SWOT Analysis
18.3.5.4. Financial Overview
18.3.5.5. Strategic Overview
18.3.6. Pharmaron Beijing Co., Ltd.
18.3.6.1. Company Overview
18.3.6.2. Product Portfolio
18.3.6.3. SWOT Analysis
18.3.6.4. Financial Overview
18.3.6.5. Strategic Overview
18.3.7. Domainex Ltd.
18.3.7.1. Company Overview
18.3.7.2. Product Portfolio
18.3.7.3. SWOT Analysis
18.3.7.4. Financial Overview
18.3.7.5. Strategic Overview
18.3.8. Thermo Fisher Scientific, Inc.
18.3.8.1. Company Overview
18.3.8.2. Product Portfolio
18.3.8.3. SWOT Analysis
18.3.8.4. Financial Overview
18.3.8.5. Strategic Overview
18.3.9. Jubilant Biosys Ltd.
18.3.9.1. Company Overview
18.3.9.2. Product Portfolio
18.3.9.3. SWOT Analysis
18.3.9.4. Financial Overview
18.3.9.5. Strategic Overview
18.3.10. Evotec SE
18.3.10.1. Company Overview
18.3.10.2. Product Portfolio
18.3.10.3. SWOT Analysis
18.3.10.4. Financial Overview
18.3.10.5. Strategic Overview
18.3.11. Eurofins Discovery
18.3.11.1. Company Overview
18.3.11.2. Product Portfolio
18.3.11.3. SWOT Analysis
18.3.11.4. Financial Overview
18.3.11.5. Strategic Overview
18.3.12. GenScript Biotech Corporation
18.3.12.1. Company Overview
18.3.12.2. Product Portfolio
18.3.12.3. SWOT Analysis
18.3.12.4. Financial Overview
18.3.12.5. Strategic Overview
List of Tables
Table 01: Global Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Workflow, 2017-2031
Table 02: Global Drug Discovery Outsourcing Market Value (`) Forecast, by Drug Molecule, 2017-2031
Table 03: Global Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Discovery Approach, 2017-2031
Table 04: Global Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Therapeutic Area, 2017-2031
Table 05: Global Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Type, 2017-2031
Table 06: Global Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by End-user, 2017-2031
Table 07: Global Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Region, 2017-2031
Table 08: North America Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Workflow, 2017-2031
Table 09: North America Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Drug Molecule, 2017-2031
Table 10: North America Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Discovery Approach, 2017-2031
Table 11: North America Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Therapeutic Area, 2017-2031
Table 12: North America Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Type, 2017-2031
Table 13: North America Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by End-user, 2017-2031
Table 14: North America Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Country, 2017-2031
Table 15: Europe Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Workflow, 2017-2031
Table 16: Europe Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Drug Molecule, 2017-2031
Table 17: Europe Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Discovery Approach, 2017-2031
Table 18: Europe Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Therapeutic Area, 2017-2031
Table 19: Europe Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Type, 2017-2031
Table 20: Europe Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by End-user, 2017-2031
Table 21: Europe Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017-2031
Table 22: Asia Pacific Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Workflow, 2017-2031
Table 23: Asia Pacific Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Drug Molecule, 2017-2031
Table 24: Asia Pacific Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Discovery Approach, 2017-2031
Table 25: Asia Pacific Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Therapeutic Area, 2017-2031
Table 26: Asia Pacific Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Type, 2017-2031
Table 27: Asia Pacific Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by End-user, 2017-2031
Table 28: Asia Pacific Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017-2031
Table 29: Latin America Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Workflow, 2017-2031
Table 30: Latin America Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Drug Molecule, 2017-2031
Table 31: Latin America Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Discovery Approach, 2017-2031
Table 32: Latin America Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Therapeutic Area, 2017-2031
Table 33: Latin America Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Type, 2017-2031
Table 34: Latin America Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by End-user, 2017-2031
Table 35: Latin America Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017-2031
Table 36: Middle East & Africa Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Workflow, 2017-2031
Table 37: Middle East & Africa Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Drug Molecule, 2017-2031
Table 38: Middle East & Africa Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Discovery Approach, 2017-2031
Table 39: Middle East & Africa Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Therapeutic Area, 2017-2031
Table 40: Middle East & Africa Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Type, 2017-2031
Table 41: Middle East & Africa Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by End-user, 2017-2031
Table 42: Middle East & Africa Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017-2031
List of Figures
Figure 01: Global Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, 2017-2031
Figure 02: Global Drug Discovery Outsourcing Market Value Share Analysis, by Workflow, 2022 and 2031
Figure 03: Global Drug Discovery Outsourcing Market Attractiveness Analysis, by Workflow, 2022-2031
Figure 04: Global Drug Discovery Outsourcing Market Revenue (US$ Bn), by Target Identification and Screening, 2017-2031
Figure 05: Global Drug Discovery Outsourcing Market Revenue (US$ Bn), by Lead Identification and Candidate Optimization, 2017-2031
Figure 06: Global Drug Discovery Outsourcing Market Revenue (US$ Bn), by Development of Disease Models, 2017-2031
Figure 07: Global Drug Discovery Outsourcing Market Revenue (US$ Bn), by Pre-formulation Studies, 2017-2031
Figure 08: Global Drug Discovery Outsourcing Market Revenue (US$ Bn), by Entire Clinical Trials, 2017-2031
Figure 09: Global Drug Discovery Outsourcing Market Revenue (US$ Bn), by Others, 2017-2031
Figure 10: Global Drug Discovery Outsourcing Market Value Share Analysis, by Drug Molecule, 2022 and 2031
Figure 11: Global Drug Discovery Outsourcing Market Value Share Analysis, by Drug Molecule, 2022 and 2031
Figure 12: Global Drug Discovery Outsourcing Market Revenue (US$ Bn), by Small Molecules, 2017-2031
Figure 13: Global Drug Discovery Outsourcing Market Revenue (US$ Bn), by Large Molecules, 2017-2031
Figure 14: Global Drug Discovery Outsourcing Market Value Share Analysis, by Discovery Approach, 2022 and 2031
Figure 15: Global Drug Discovery Outsourcing Market Revenue (US$ Bn), by Empirical Drug Discovery, 2017-2031
Figure 16: Global Drug Discovery Outsourcing Market Revenue (US$ Bn), by Rational Drug Discovery, 2017-2031
Figure 17: Global Drug Discovery Outsourcing Market Value Share Analysis, by Therapeutic Area, 2022 and 2031
Figure 18: Global Drug Discovery Outsourcing Market Revenue (US$ Bn), by Anti-infective, 2017-2031
Figure 19: Global Drug Discovery Outsourcing Market Revenue (US$ Bn), by Cardiovascular, 2017-2031
Figure 20: Global Drug Discovery Outsourcing Market Revenue (US$ Bn), by Central Nervous System, 2017-2031
Figure 21: Global Drug Discovery Outsourcing Market Revenue (US$ Bn), by Dermatology, 2017-2031
Figure 22: Global Drug Discovery Outsourcing Market Revenue (US$ Bn), by Endocrine, 2017-2031
Figure 23: Global Drug Discovery Outsourcing Market Revenue (US$ Bn), by Gastrointestinal, 2017-2031
Figure 24: Global Drug Discovery Outsourcing Market Revenue (US$ Bn), by Genitourinary System, 2017-2031
Figure 25: Global Drug Discovery Outsourcing Market Revenue (US$ Bn), by Immunomodulation, 2017-2031
Figure 26: Global Drug Discovery Outsourcing Market Revenue (US$ Bn), by Oncology, 2017-2031
Figure 27: Global Drug Discovery Outsourcing Market Revenue (US$ Bn), by Ophthalmology, 2017-2031
Figure 28: Global Drug Discovery Outsourcing Market Revenue (US$ Bn), by Respiratory System, 2017-2031
Figure 29: Global Drug Discovery Outsourcing Market Revenue (US$ Bn), by Others, 2017-2031
Figure 30: Global Drug Discovery Outsourcing Market Value Share Analysis, by Type, 2022 and 2031
Figure 31: Global Drug Discovery Outsourcing Market Attractiveness Analysis, by Type, 2022-2031
Figure 32: Global Drug Discovery Outsourcing Market Revenue (US$ Bn), by Chemistry Services, 2017-2031
Figure 33: Global Drug Discovery Outsourcing Market Revenue (US$ Bn), by Biology Services, 2017-2031
Figure 34: Global Drug Discovery Outsourcing Market Value Share Analysis, by End-user, 2022 and 2031
Figure 35: Global Drug Discovery Outsourcing Market Attractiveness Analysis, by End-user, 2022-2031
Figure 36: Global Drug Discovery Outsourcing Market Revenue (US$ Bn), by Pharmaceutical Companies, 2017-2031
Figure 37: Global Drug Discovery Outsourcing Market Revenue (US$ Bn), by Biotechnology Companies, 2017-2031
Figure 38: Global Drug Discovery Outsourcing Market Revenue (US$ Bn), by Academic Institutes, 2017-2031
Figure 39: Global Drug Discovery Outsourcing Market Value Share Analysis, by Region, 2022 and 2031
Figure 40: Global Drug Discovery Outsourcing Market Attractiveness Analysis, by Region, 2022-2031
Figure 41: North America Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, 2017-2031
Figure 42: North America Drug Discovery Outsourcing Market Value Share Analysis, by Workflow, 2022 and 2031
Figure 43: North America Drug Discovery Outsourcing Market Attractiveness Analysis, by Workflow, 2022-2031
Figure 44: North America Drug Discovery Outsourcing Market Value Share Analysis, by Drug Molecule, 2022 and 2031
Figure 45: North America Drug Discovery Outsourcing Market Attractiveness Analysis, by Drug Molecule, 2022-2031
Figure 46: North America Drug Discovery Outsourcing Market Value Share Analysis, by Discovery Approach, 2022 and 2031
Figure 47: North America Drug Discovery Outsourcing Market Attractiveness Analysis, by Discovery Approach, 2022-2031
Figure 48: North America Drug Discovery Outsourcing Market Value Share Analysis, by Therapeutic Area, 2022 and 2031
Figure 49: North America Drug Discovery Outsourcing Market Attractiveness Analysis, by Therapeutic Area, 2022-2031
Figure 50: North America Drug Discovery Outsourcing Market Value Share Analysis, by Type, 2022 and 2031
Figure 51: North America Drug Discovery Outsourcing Market Attractiveness Analysis, by Type, 2022-2031
Figure 52: North America Drug Discovery Outsourcing Market Value Share Analysis, by End-user, 2022 and 2031
Figure 53: North America Drug Discovery Outsourcing Market Attractiveness Analysis, by End-user, 2022-2031
Figure 54: North America Drug Discovery Outsourcing Market Value Share Analysis, by Country, 2022 and 2031
Figure 55: North America Drug Discovery Outsourcing Market Attractiveness Analysis, by Country, 2022-2031
Figure 56: Europe Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, 2017-2031
Figure 57: Europe Drug Discovery Outsourcing Market Value Share Analysis, by Workflow, 2022 and 2031
Figure 58: Europe Drug Discovery Outsourcing Market Attractiveness Analysis, by Workflow, 2022-2031
Figure 59: Europe Drug Discovery Outsourcing Market Value Share Analysis, by Drug Molecule, 2022 and 2031
Figure 60: Europe Drug Discovery Outsourcing Market Attractiveness Analysis, by Drug Molecule, 2022-2031
Figure 61: Europe Drug Discovery Outsourcing Market Value Share Analysis, by Discovery Approach, 2022 and 2031
Figure 62: Europe Drug Discovery Outsourcing Market Attractiveness Analysis, by Discovery Approach, 2022-2031
Figure 63: Europe Drug Discovery Outsourcing Market Value Share Analysis, by Therapeutic Area, 2022 and 2031
Figure 64: Europe Drug Discovery Outsourcing Market Attractiveness Analysis, by Therapeutic Area, 2022-2031
Figure 65: Europe Drug Discovery Outsourcing Market Value Share Analysis, by Type, 2022 and 2031
Figure 66: Europe Drug Discovery Outsourcing Market Attractiveness Analysis, by Type, 2022-2031
Figure 67: Europe Drug Discovery Outsourcing Market Value Share Analysis, by End-user, 2022 and 2031
Figure 68: Europe Drug Discovery Outsourcing Market Attractiveness Analysis, by End-user, 2022-2031
Figure 69: Europe Drug Discovery Outsourcing Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 70: Europe Drug Discovery Outsourcing Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
Figure 71: Asia Pacific Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, 2017-2031
Figure 72: Asia Pacific Drug Discovery Outsourcing Market Value Share Analysis, by Workflow, 2022 and 2031
Figure 73: Asia Pacific Drug Discovery Outsourcing Market Attractiveness Analysis, by Workflow, 2022-2031
Figure 74: Asia Pacific Drug Discovery Outsourcing Market Value Share Analysis, by Drug Molecule, 2022 and 2031
Figure 75: Asia Pacific Drug Discovery Outsourcing Market Attractiveness Analysis, by Drug Molecule, 2022-2031
Figure 76: Asia Pacific Drug Discovery Outsourcing Market Value Share Analysis, by Discovery Approach, 2022 and 2031
Figure 77: Asia Pacific Drug Discovery Outsourcing Market Attractiveness Analysis, by Discovery Approach, 2022-2031
Figure 78: Asia Pacific Drug Discovery Outsourcing Market Value Share Analysis, by Therapeutic Area, 2022 and 2031
Figure 79: Asia Pacific Drug Discovery Outsourcing Market Attractiveness Analysis, by Therapeutic Area, 2022-2031
Figure 80: Asia Pacific Drug Discovery Outsourcing Market Value Share Analysis, by Type, 2022 and 2031
Figure 81: Asia Pacific Drug Discovery Outsourcing Market Attractiveness Analysis, by Type, 2022-2031
Figure 82: Asia Pacific Drug Discovery Outsourcing Market Value Share Analysis, by End-user, 2022 and 2031
Figure 83: Asia Pacific Drug Discovery Outsourcing Market Attractiveness Analysis, by End-user, 2022-2031
Figure 84: Asia Pacific Drug Discovery Outsourcing Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 85: Asia Pacific Drug Discovery Outsourcing Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
Figure 86: Latin America Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, 2017-2031
Figure 87: Latin America Drug Discovery Outsourcing Market Value Share Analysis, by Workflow, 2022 and 2031
Figure 88: Latin America Drug Discovery Outsourcing Market Attractiveness Analysis, by Workflow, 2022-2031
Figure 89: Latin America Drug Discovery Outsourcing Market Value Share Analysis, by Drug Molecule, 2022 and 2031
Figure 90: Latin America Drug Discovery Outsourcing Market Attractiveness Analysis, by Drug Molecule, 2022-2031
Figure 91: Latin America Drug Discovery Outsourcing Market Value Share Analysis, by Discovery Approach, 2022 and 2031
Figure 92: Latin America Drug Discovery Outsourcing Market Attractiveness Analysis, by Discovery Approach, 2022-2031
Figure 93: Latin America Drug Discovery Outsourcing Market Value Share Analysis, by Therapeutic Area, 2022 and 2031
Figure 94: Latin America Drug Discovery Outsourcing Market Attractiveness Analysis, by Therapeutic Area, 2022-2031
Figure 95: Latin America Drug Discovery Outsourcing Market Value Share Analysis, by Type, 2022 and 2031
Figure 96: Latin America Drug Discovery Outsourcing Market Attractiveness Analysis, by Type, 2022-2031
Figure 97: Latin America Drug Discovery Outsourcing Market Value Share Analysis, by End-user, 2022 and 2031
Figure 98: Latin America Drug Discovery Outsourcing Market Attractiveness Analysis, by End-user, 2022-2031
Figure 99: Latin America Drug Discovery Outsourcing Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 100: Latin America Drug Discovery Outsourcing Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
Figure 101: Middle East & Africa Drug Discovery Outsourcing Market Value (US$ Bn) Forecast, 2017-2031
Figure 102: Middle East & Africa Drug Discovery Outsourcing Market Value Share Analysis, by Workflow, 2022 and 2031
Figure 103: Middle East & Africa Drug Discovery Outsourcing Market Attractiveness Analysis, by Workflow, 2022-2031
Figure 104: Middle East & Africa Drug Discovery Outsourcing Market Value Share Analysis, by Drug Molecule, 2022 and 2031
Figure 105: Middle East & Africa Drug Discovery Outsourcing Market Attractiveness Analysis, by Drug Molecule, 2022-2031
Figure 106: Middle East & Africa Drug Discovery Outsourcing Market Value Share Analysis, by Discovery Approach, 2022 and 2031
Figure 107: Middle East & Africa Drug Discovery Outsourcing Market Attractiveness Analysis, by Discovery Approach, 2022-2031
Figure 108: Middle East & Africa Drug Discovery Outsourcing Market Value Share Analysis, by Therapeutic Area, 2022 and 2031
Figure 109: Middle East & Africa Drug Discovery Outsourcing Market Attractiveness Analysis, by Therapeutic Area, 2022-2031
Figure 110: Middle East & Africa Drug Discovery Outsourcing Market Value Share Analysis, by Type, 2022 and 2031
Figure 111: Middle East & Africa Drug Discovery Outsourcing Market Attractiveness Analysis, by Type, 2022-2031
Figure 112: Middle East & Africa Drug Discovery Outsourcing Market Value Share Analysis, by End-user, 2022 and 2031
Figure 113: Middle East & Africa Drug Discovery Outsourcing Market Attractiveness Analysis, by End-user, 2022-2031
Figure 114: Middle East & Africa Drug Discovery Outsourcing Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 115: Middle East & Africa Drug Discovery Outsourcing Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Drug Discovery Outsourcing Market
